GlassScriptPhysician profile
Vasily Rozenbaum
NPI 1245727973
$5,866.07
in general payments reported to CMS, 2019-2025
43 companies · $843 in 2025
The $843 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.26 · 2022: $757 · 2023: $2,552 · 2024: $1,665 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,058 · Education: $1.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,058.33 |
| Education | $1.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,028.79 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $672.28 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $622.63 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $517.25 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $313.69 | 2023-2025 | Auvelity, Sunosi |
| Pfizer INC. | $258.77 | 2023-2025 | |
| Tris Pharma INC | $247.58 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Glaxosmithkline, LLC. | $225.47 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $191.01 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Edwards Lifesciences Corporation | $151.69 | 2022 | |
| Phathom Pharmaceuticals, INC. | $144.52 | 2024-2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $124.01 | 2022 | |
| Amgen INC. | $122.09 | 2022-2025 | Otezla, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $83.55 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $82.82 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasily Rozenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.